The status of new anticoagulants

被引：73

作者：

Bates, Shannon M.

Weitz, Jeffrey I.

机构：

[1] Henderson Res Ctr, Hamilton, ON L8V 1C3, Canada

[2] McMaster Univ, Dept Med, Hamilton, ON L8S 4L8, Canada

[3] McMaster Univ, Dept Biochem, Hamilton, ON L8S 4L8, Canada

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2006年 / 134卷 / 01期

关键词：

anticoagulant; antithrombotic; venous thromboembolism; arterial thromboembolism; pentasaccharide;

D O I：

10.1111/j.1365-2141.2006.06134.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

s Currently available anticoagulants include heparin, low-molecular weight heparin, fondaparinux and warfarin. Despite advances with low-molecular weight heparin and fondaparinux, the currently available agents have limitations that have provided the impetus for the development of new drugs for prevention and treatment of both venous and arterial thromboembolism. Novel anticoagulants targeting specific steps in coagulation are in various stages of development. This paper reviews the pharmacology of these new agents and describes the results of clinical trials with new anticoagulants in more advanced stages of clinical testing.

引用

页码：3 / 19

页数：17

共 162 条

[1] Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: A multicenter, randomized, placebo-controlled, single-blind, dose escalation study [J].

Abraham, E ;

Reinhart, K ;

Svoboda, P ;

Seibert, A ;

Olthoff, D ;

Dal Nogare, A ;

Postier, R ;

Hempelmann, G ;

Butler, T ;

Martin, E ;

Zwingelstein, C ;

Percell, S ;

Shu, V ;

Leighton, A ;

Creasey, AA .

CRITICAL CARE MEDICINE, 2001, 29 (11) :2081-2089

[2] Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis -: A randomized controlled trial [J].

Abraham, E ;

Reinhart, K ;

Opal, S ;

Demeyer, I ;

Doig, C ;

Rodriguez, AL ;

Beale, R ;

Svoboda, P ;

Laterre, PF ;

Simon, S ;

Light, B ;

Spapen, H ;

Stone, J ;

Seibert, A ;

Peckelsen, C ;

De Deyne, C ;

Postier, R ;

Pettilä, V ;

Sprung, CL ;

Artigas, A ;

Percell, SR ;

Shu, V ;

Zwingelstein, C ;

Tobias, J ;

Poole, L ;

Stolzenbach, JC ;

Creasey, AA .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (02) :238-247

[3] Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death [J].

Abraham, E ;

Laterre, P ;

Garg, R ;

Levy, H ;

Talwar, D ;

Trzaskoma, BL ;

Francois, B ;

Guy, JS ;

Bruckmann, M ;

Rea-Neto, A ;

Rossaint, R ;

Perrotin, D ;

Sablotzki, A ;

Arkins, N ;

Utterback, BG ;

Macias, WL .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (13) :1332-1341

[4] Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery [J].

Agnelli, G ;

Bergqvist, D ;

Cohen, AT ;

Gallus, AS ;

Gent, M .

BRITISH JOURNAL OF SURGERY, 2005, 92 (10) :1212-1220

[5]

Agnelli G, 2005, BLOOD, V106, p85A

[6]

Albers GW, 2005, JAMA-J AM MED ASSOC, V293, P690

[7]

Albers GW, 2003, LANCET, V362, P1691

[8] First experience with direct, selective factor Xa inhibition in patients with non-ST-elevation acute coronary syndromes: results of the XaNADU-ACS trial [J].

Alexander, JH ;

Yang, H ;

Becker, RC ;

Kodama, K ;

Goodman, S ;

Dyke, CK ;

Kleiman, NS ;

Hochman, JS ;

Berger, PB ;

Cohen, EA ;

Lincoff, AM ;

Burton, JR ;

Bovill, EG ;

Kawai, C ;

Armstrong, PW ;

Harrington, RA .

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2005, 3 (03) :439-447

[9] Initial experience with factor-Xa inhibition in percutaneous coronary intervention: the XaNADU-PCI pilot [J].

Alexander, JH ;

Dyke, CK ;

Yang, H ;

Becker, RC ;

Hasselblad, V ;

Zillman, LA ;

Kleiman, NS ;

Hochman, JS ;

Berger, PB ;

Cohen, EA ;

Lincoff, AM ;

Saint-Jacques, H ;

Chetcuti, S ;

Burton, JR ;

Buergler, JM ;

Spence, FP ;

Shimoto, Y ;

Robertson, TL ;

Kunitada, S ;

Bovill, EG ;

Armstrong, PW ;

Harrington, RA .

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2004, 2 (02) :234-241

[10] Absence of cross-reactivity of SR90107A/ORG31540 pentasaccharide with antibodies to heparin-PF4 complexes developed in heparin-induced thrombocytopenia [J].

Amiral, J ;

Lormeau, JC ;

MarfaingKoka, A ;

Vissac, AM ;

Wolf, M ;

BoyerNeumann, C ;

Tardy, B ;

Herbert, JM ;

Meyer, D .

BLOOD COAGULATION & FIBRINOLYSIS, 1997, 8 (02) :114-117

← 1 2 3 4 5 6 7 8 9 10 →